Rituximab in B-Cell Hematologic Malignancies: A Review of 20 Years of Clinical Experience
Université Claude Bernard Lyon 1 · Hospices Civils de Lyon · +5 more institutions
Abstract
Rituximab is a human/murine, chimeric anti-CD20 monoclonal antibody with established efficacy, and a favorable and well-defined safety profile in patients with various CD20-expressing lymphoid malignancies, including indolent and aggressive forms of B-cell non-Hodgkin lymphoma. Since its first approval 20 years ago, intravenously administered rituximab has revolutionized the treatment of B-cell malignancies and has become a standard component of care for follicular lymphoma, diffuse large B-cell lymphoma, chronic lymphocytic leukemia, and mantle cell lymphoma. For all of these diseases, clinical trials have demonstrated that rituximab not only prolongs the time to disease progression but also extends overall…
Citation impact
- FWCI
- 20.00
- Percentile
- 100%
- References
- 166
Authors
8Topics & keywords
- Rituximab
- Medicine
- Obinutuzumab
- CD20
- Ofatumumab
- Lymphoma
- Chronic lymphocytic leukemia
- Follicular lymphoma
- Good health and well-being